Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
87M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
51.6M
-
Shares change
-
+3.63M
-
Total reported value, excl. options
-
$755M
-
Value change
-
+$58.6M
-
Put/Call ratio
-
5.94
-
Number of buys
-
63
-
Number of sells
-
-46
-
Price
-
$14.62
Significant Holders of Immunome Inc. - COMMON STOCK (IMNM) as of Q3 2024
140 filings reported holding IMNM - Immunome Inc. - COMMON STOCK as of Q3 2024.
Immunome Inc. - COMMON STOCK (IMNM) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.6M shares
of 87M outstanding shares and own 59.31% of the company stock.
Largest 10 shareholders include T. Rowe Price Investment Management, Inc. (5.76M shares), Redmile Group, LLC (4.89M shares), FMR LLC (4.22M shares), BlackRock, Inc. (3.98M shares), EcoR1 Capital, LLC (3.88M shares), JANUS HENDERSON GROUP PLC (3.49M shares), VANGUARD GROUP INC (3.13M shares), STATE STREET CORP (2.19M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.04M shares), and Jefferies Financial Group Inc. (1.88M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.